ARID1A and the SWI/SNF Complex: Chromatin Remodelling in Cancer

What SWI/SNF Does

DNA is wrapped around histone octamers to form nucleosomes, which by default block access to regulatory sequences. The SWI/SNF complex hydrolyses ATP through its catalytic subunit (SMARCA4 or SMARCA2) to reposition or remove nucleosomes at promoters and enhancers.

This makes it essential for lineage-specific gene expression, differentiation and, in some contexts, for the activity of tumour-suppressor programmes and DNA repair.

ARID1A as a Tumour Suppressor

ARID1A is a DNA-binding subunit that helps target the complex to specific sites. Loss-of-function ARID1A mutations are the most common SWI/SNF lesion and recur in ovarian clear cell and endometrioid carcinoma, endometrial cancer, gastric cancer, bladder cancer and cholangiocarcinoma.

Most ARID1A mutations are truncating and lead to loss of protein, which can be detected by immunohistochemistry and is used diagnostically in some tumours.

Other Subunits and Distinct Cancers

SMARCB1 loss defines malignant rhabdoid tumours and epithelioid sarcoma. SMARCA4 loss drives small cell carcinoma of the ovary hypercalcaemic type and a subset of aggressive thoracic tumours. PBRM1 loss is common in clear cell renal cell carcinoma.

Each subunit loss produces a characteristic tumour spectrum, so the specific gene matters.

Emerging Vulnerabilities

SWI/SNF-mutant cancers can depend on residual complex activity or on compensating pathways. ARID1A-deficient cells show sensitivity to inhibition of the paralogue ARID1B, to EZH2 inhibitors, to PARP and ATR inhibitors in some models, and altered response to immune-checkpoint blockade.

SMARCB1- or SMARCA4-deficient tumours are being treated with EZH2 inhibitors, with tazemetostat approved for epithelioid sarcoma. Most other approaches remain investigational.

Interpretation Notes

A SWI/SNF subunit alteration should be identified specifically (ARID1A vs SMARCB1 vs SMARCA4 and so on), because the tumour associations and any therapeutic leads differ.

Loss of subunit protein by immunohistochemistry supports functional inactivation, complementing sequencing.

Key Takeaways

• ·SWI/SNF (BAF) uses ATP to reposition nucleosomes and open regulatory DNA.
• ·Its subunits are collectively mutated in about 20 percent of cancers; ARID1A loss is the most common.
• ·Different subunit losses (SMARCB1, SMARCA4, PBRM1) define different tumour types.
• ·Synthetic-lethal leads include EZH2, ARID1B and DNA-damage-response targeting, mostly investigational.